Response of omalizumab in normocomplementemic urticarial vasculitis.

Chen, Yu-Di; Krause, Karoline; Tu, Ping; Zhao, Zuo-Tao; Maurer, Marcus

Chen, Yu-Di; Krause, Karoline; Tu, Ping; Zhao, Zuo-Tao; Maurer, Marcus.

Afiliação

Chen YD; Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China; National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Krause K; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Tu P; Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China; National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Zhao ZT; Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China; National Clinical Research Center for Skin and Immune Diseases, Beijing, China. Electronic address: zhaozuotaotao@163.com.
Maurer M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address: marcus.maurer@charite.de.

J Allergy Clin Immunol Pract ; 8(6): 2114-2117.e2, 2020 06.

Article em En | MEDLINE | ID: mdl-32145404

Assuntos

Urticária; Vasculite Leucocitoclástica Cutânea; Humanos; Omalizumab/uso terapêutico; Urticária/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Urticária / Vasculite Leucocitoclástica Cutânea Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google